Changqing Su

5PUBLICATIONS
2CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Dec 22, 2025
Oncolytic adenovirus delivery of neoantigens sensitizes low-mutation tumors to anti-PD-1 therapy and prevents metastasis.

Ke-Yu Shen, Shi-Zhe Yu, Ying-Han Su

|Jul 27, 2022
Chimeric Oncolytic Adenovirus Armed Chemokine Rantes for Treatment of Breast Cancer.

Lin Ang, Jiang Li, Hui Dong

|May 24, 2022
Triple-serotype chimeric oncolytic adenovirus exerts multiple synergistic mechanisms against solid tumors.

Yinghan Su, Jiang Li, Weidan Ji

|Apr 29, 2022
miR-2392 functions as tumour suppressor and inhibits malignant progression of hepatocellular carcinoma via directly targeting JAG2.

Bin Sun, Weidan Ji, Chunying Liu

|Dec 07, 2017
I131 reinforces antitumor activity of metuximab by reversing epithelial-mesenchymal transition via VEGFR-2 signaling in hepatocellular carcinoma.

Lu Wu, Bin Sun, Xuejing Lin

Pageof 1